百奥赛图：与育世博达成进一步合作，共同推进同类首创双特异性抗体双药物偶联物（BsAD2C）项目

Core Viewpoint - Baiaosaitu (Beijing) Pharmaceutical Technology Co., Ltd. has entered into an option and licensing agreement with Yushibo to systematically evaluate the bispecific antibody-drug conjugate (BsADC) projects, aiming to accelerate the development of bispecific antibody-drug conjugates (BsAD2C) [1] Group 1 - The agreement grants Yushibo an option to obtain global exclusive rights to two BsADC projects from Baiaosaitu [1] - Baiaosaitu is entitled to receive an upfront payment for the option, and upon Yushibo exercising the option, Baiaosaitu will receive additional payments including option exercise fees, development and regulatory milestone payments, commercialization milestone payments, and sales royalties [1] - Specific financial terms of the agreement have not been disclosed [1]